BOSTON, Sept. 15, 2011 /PRNewswire/ — Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company has shown a 32% increase in Breast Endoscopy sales for the period of June through August 2011 as compared to the prior year. Management recently reported an increase in demand for its new MammoView® instrument line.
The MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions that are undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
Sales of Breast Endoscopy Components for the period of June through August 2011 were $51,630, which represents a 32% increase from the prior year. The Solos MammoView® instrument line is featured on the Company’s new website www.solosendoscopy.com.
“The fact that we have taken this tremendous product from concept phase to sales in dozens of hospitals across the Country is extremely gratifying. We expect to see continued sales improvement in the 4th Quarter” stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Amanda Segersten, email@example.com
SOURCE Solos Endoscopy, Inc.